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Summary.-A single dose of 200 mg/kg razoxane protected mice against the sub-
chronic lethal effects (i.e. within 21 days) of 10 mg/kg daunomycin. When the razoxane
dose was split into 2 doses of 100 mg/kg, even betterprotection against higher doses of
daunomycin was obtained. The best protective effect was seen when the razoxane was
given 24 h before or simultaneously with the daunomycin, and it was still present,
though less, 24 h later.
Histopathological examination to determine the site of protection showed it to be in
the small bowel. Marrow and cardiac tissue showed no evident changes when
examined by light microscopy.
IT HAS BEEN DEMONSTRATED in a series
ofexperiments (Herman et al., 1974, 1979)
that the toxicity of the anthracycline
daunomycin (DM) can be greatly reduced
by the administration of razoxane (RZ,
ICRF-159). Others (Woodman et al., 1975)
have found that not only will RZ reduce
the toxicity ofDM, but it will also enhance
its antitumour activity. The mechanism
whereby this distinct improvement in the
therapeuticratioofDMisobtainedremains
unclear, and it seemed of some interest
therefore to define it more accurately.
MATERIALS AND METHODS
Drugs.-Daunomycin (DM, Rhone Polenc)
was dissolved in 0.9%o saline and used im-
mediately or stored at 4°C for a maximum of
24 h. Razoxane (RZ, Imperial Chemical Inds.)
was milled over-night in CMC (0-5%o carboxy-
methyl cellulose in 0.9% saline) and stored
until required at4°C for not more than 5 days.
Both DM and RZ were injected i.p. into
BDF1 (C57/B6 female x DBA/2 male) female
mice weighing 18-20 g.
In a single-dose schedule, doses of 50, 100,
150 or 200 mg/kg RZ were given at the same
time as 10, 20, 25 or 30 mg/kg DM. In a split-
dose schedule, 100 mg/kg RZ was given at
24 and 18 h before 10, 20,25 or 30 mg/kg DM.
In a further experiment, 200 mg/kg RZ was
given over a period ranging from 96 h before
to 48 h after the administration of 10 mg/kg
DM
In multiple-dose schedules doses of RZ
ranging from 50 to 400 mg/kg were given on
Days 1, 5 and 9, and DM (4 or 6 mg/kg) was
given 24 h after each RZ dose.
Evaluation of toxicity.-In the single-dose
schedules, either the number ofdays to 100%
mortality in each group, or the number of
survivors after 21 days was recorded, as mice
surviving beyond that time survived in-
definitely. In the multiple-dose schedules the
number ofmice in each group surviving for at
least 30 days was noted.
Histopathology.-Extensive histopathologi-
cal examinations were made on the following
groups of animals:
Group 1-200 mg/kg RZ i.p. on Day 1
Group 2-10 mg/kg DM i.p. on Day 2
Group 3-200 mg/kg RZ i.p. on Day 1
followed 24 h later by 10 mg/kg DM i.p.
Group 4-saline controls
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Mice in Group 2 which showed obvious
symptoms of DM toxicity were killed and an
equal number of mice from each of the other
groups was killed at the same time. 'Sternal
and femoral marrow and whole blood smears
were prepared from all mice and stained with
Leishman's.
Heart, spleen, lungs, kidneys, liver, thymus
and small intestines were fixed in 10% neutral
buffered formol saline and processed for para-
ffin embedding. Sections were stained with
haemotoxylin and eosin. In a similar experi-
ment the whole of the intestinal tract from
pylorustoanuswasremovedfrom each mouse
and fixed in 10% neutral buffered formol
saline, after which pieces 1 cm long were
taken from duodenum, jejunum, ileum and
colon, and embedded in paraffin for longi-
tudinal sectioning. Sections were stained with
buffered dilute Giemsa.
In another experiment designed to study
cardiac changes, one group of mice received
20 mg/kg DM i.p. alone, while another re-
ceived 200 mg/kg RZ i.p. 24 h before the same
dose ofDM. Micewere killed onDays 3, 4,7, 8
and 9 after the DM. The hearts were removed
and prepared for sectioning. Sections were
stained by either H. and E. or diastase-
periodic-acid-Schiff.
RESULTS
Survival of mice after daunomycin and
razoxane treatment
In the single-dose schedule, the timing
of the dose of RZ in relation to that of
DM was found to be important (Fig. 1).
The protective effect of RZ (200 mg/kg)
was greatest when given 24 h before, or at
the same time as 10 mg/kg DM, when 6/6
of the mice survived. Survivors were re-
duced to 4/6 in the groups given RZ 48 h
before, or 24 h after DM injection. RZ
96 72 48 24 0 24 48 H
*-------BEFORE4 -'--AFTER--_
DM
Time Of Administration Of RZ In Relation To DM
FIG. 1.-Survival of mice given a single dose
of200mg/kgrazoxane (RZ) attimesranging
from 96 h before to 48 h after the admini-
stration of a single dose of 10mg/kg dauno-
mycin (DM).
given more than 48 h before DM was
ineffective. RZ given 48 h after DM was
not only ineffective, but proved to be
much more toxic than DM alone. With
this dosage scheme, 50% of the mice died
10 days (median survival time) after the
DM, compared with an MST of 15 days
when the DM was given alone.
Table 1 shows the effects of increasing
doses of RZ with a constant dose of DM.
Tables II and III demonstrate the protec-
tive effect of a constant dose of RZ (200
mg/kg) against toxicity induced by in-
creasing doses of DM. RZ gave complete
protection against 10 mg/kg DM but less
against higher doses.
Table III compares a single dose of RZ
with the same total dose in two equal
parts. 100 mg/kg RZ given at 24 h and
again at 18 h before DM had a greater
protective effect than a single dose of 200
mg/kg at the same time as DM.
TABLE 1.-Survival of mice given varying doses of razoxane (RZ) and 10 mg/kq
daunomycin (DM)
RZ ,-
(mg/kg) 8 9
0 100 67
50 100 100
100 )
150 Full protection
200
% survivors on days following administration ofdrugs
10
33
100
11
17
100
12 13 14 15 16 17
0
83
- 21
83 67 67 50 17 17
DM and RZ were administered simultaneously in single doses. 6 mice per group.
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TABLE II.-The effect of razoxane (RZ) on mortality of mice induced by varying doses of
daunomycin (DIM)
% survivrors on days following administration ofdIrugs
5 6 7 8 9 10 11
100 100 100 83 83 83 66
100 100 100 100 100 100 100
83 33 33 16 0
100 66 50 33 16 0
0
0
0
0
DM and RZ were a(dministered simultaneously in single doses. 6 mice per group.
TABLE III.-Effect ofsplit doses of razoxane (RZ) on protection against daunomycin (DM)
mortality of mice (6 mice/group)
DAM
(mg/kg)
at time 0
10
10
20
20
25
25
30
30
Timing of RZ
RZ in relation
(mg/kg) to DMI
200 0
100+ -24 II
100 - 18 li
200 0
100+ -24 i
100 -18 }
200 0
100+ -24 hi
100 -18 Ii
200 0
100+ -24 hi
100 -18 Iibefore
% survivors on days following administiatioii of drugs
3 4 5 6 7 8 9 10 11 12 13
100 100 100 100 100 100 100 100 100 100 100
100 100 100 100 100 100 100 100 100 100 100
100 100 100 66 50 33
100 100 100 100 100 100
100 83 0
100 100 100 83 83 66
100
100
Fig. 2 shows that in a multiple-dose
schedule, using doses of 4 and 6 mg/kg
DM, 200 mg/kg ofRZprovides almost com-
plete protection. Doses of 50, 100 and
150 mg/kg, however, only partially pro-
tect, especially against 6 mg/kg DM. 400
mg/kg RZ significantly reduces the pro-
tection against DM. The increase in
mortality over that seen with 200 mg/kg
most likely reflects additive toxicity of the
two drugs.
As may be seen from Fig. 3, 200 mg/kg
RZ and 4 mg/kg DM plus RZ both caused
considerable weight loss in the mice, from
which however they recovered. Mice
receiving DM alone all died without
recovery of weight loss.
Histopathological findings
No marked changes were found in
marrow from mice treated with single
doses of DM, RZ or their combination.
59*
16
83
0
66 50 16 0
66 50 33 33 33
50 0
83 66 50 0
Total blood counts and differentials also
appeared to be within the normal range.
Histologically lungs, kidney and liver
appeared to be normal.
Hearts up to 9 days after treatment from
mice given DM alone in both single and
multiple doses showed no distinct cardio-
myopathy in light microscopy.
Marked histopathological changes were
seen in the intestines of mice receiving DM
alone, with severe damage to the mu-
cosa throughout the gut in 2 mice and less
severe damage in the other 2 of this group.
In the 2 most severely affected, the small-
intestine villi were oedematous, had shed
their epithelium, particularly at the tips,
and were shorter and reduced in number
(Figs 5 and 6). Peyer's patches showed
reduction in lymphoid tissue compared
with the number of histiocytes in their
sinuses (Fig. 6). In the colons of these 2
mice the epithelium was atrophic and
D)l
(mg/kg)
10
10
20
20
25
25
30
30
RZ
(mg/kg)
200
200
200
200
3
100
100
100
100
100
100
100
100
4
100
100
100
100
20
83
33
50
12
33
100
13
0
100
873G. WANG ET AL.
0
V)
:0%
80-
046 046 046 046 046 046 DMmg/Kg
0 50 100 150 200 400 RZ mg/Kg
FcI. 2.-Survival of mice in a mtiltiple-dose schedule. RZ was given on Days 1, 5 and 9 and D)M was given
24h&after each dose of RZ.
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FiG. 3.-Weight chlange of mice. 200 mg/kg RZ was given on Days 1, 5 and 9 and 4 mg/kg DM was given
on Days 2, 6 and 10. 0, RZ alone; 0, RZ and DM; , D)M alone; x untreated controls.
mucus secretion had greatly increased, so
thatin one mousethe cryptsweredistended
with mucus and had flattened epithelium
(Fig. 7). In both mice the wall was lined
by a thick mucus, trapping epithelial
debris. Brunner's glands were only in-
cluded in the duodenal section of one of
these mice, and compared with the control
(Fig. 4) the acini had a flatter epithelium
and appeared slightly distended.
In the other 2 less severely affected
mice treated with DM, marked oedema of
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Fia. 4.-Duodenum: (a) control, (b) DMalone;
atrophic change in villi and Brunner's
gland, (c) DM and RZ; normal appearance.
All sections stained with Giemsa.
the villi of the small intestine was ap-
parent in one mouse, with no appreciable
damage to the mucosa of the colon. The
other mouse had some atrophy of colonic
mucosa, with excessive mucus secretion.
The combined RZ +DM treatment how-
ever produced very little change in the
intestinal tracts, which appeared similar to
thoseofthe saline controls. Brunner'sgland
(Fig. 4) seemed not very different from
(c)
FIG. 5.-Jejunum: (a) control, (b) DM alone;
severe oedema and shedding ofvilli, (c) DM
+RZ; a little oedema of villi and slight
atrophy.
those of the controls and Peyer's patches
(Fig. 6) showed no evident pathology. The
mucosa ofthe colons also appeared normal
(Fig. 7)
The sections of intestines ofmice treated
with RZ alone appeared no different
from those of normal mice.
DISCUSSION
Reduction of anticancer drug toxicity
has been achieved in a number of ways,
(a)
. .;A4
I)
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FIG. 6.-Ileum: (a) control (b) DM alone;
atrophy and oedema of villi and hypopla-
sia of Peyer's patch, (c) DM+RZ; normal
appearance.
and some of the more unexpected have
been due to the combination of two anti-
cancer drugs (Goldin et al., 1974; Millar
et al., 1978) depressing each other's
toxicity but at the same time increasing
the combined activity. It seems clear from
our studies that the acute DM gut toxicity
has been drastically reduced by RZ.
The protective effect of RZ seems great-
(c)
FIG. 7. Colon: (a) control, (b) DM alone;
atrophic crypts plugged with excessive
mucus secretion, (c) DM+RZ; normal
appearance.
er when given before DM, which is perhaps
not surprising, but the fact that pro-
tection can still clearly be demonstrated
when RZ is given 24 h after the DM would
seem to indicate that the mechanism in-
volved acts during a similar time course to
the renewal of the crypt cells which seem
to be chiefly affected. One might specu-
late therefore that the protective effect
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of RZ occurred during the replication of
the crypt cells.
It is not possible from the present ex-
periments to say which drug influences
which, but since both drugs are chelating
agents it may be that they compete for the
same ions or free radicals which may be
more involved in the induction of toxi-
city than in the inhibition of replica-
tion.
The limited clinical use of DM is due to
the combined drawbacks of modest anti-
tumour activity (except in adult leu-
kaemias), dose-liniting cardiotoxicity and
potent carcinogenicity. If these side-
effects could be reduced by simultaneous
administration of RZ, the basis for a
re-exploration of this drug in cancer
treatment might be provided. The pos-
sibility of a concomitant increase in
activity would make such a re-explora-
tion doubly attractive, particulary in
adult acute leukaemia, where although
remission rates with current regimes using
DM have reached 75-80%, survival for
more than 18 months is still uncommon.
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